REGENXBIO Inc. (NASDAQ:RGNX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
REGENXBIO Inc. (NASDAQ:RGNX) gained 10.33 Percent and closed its previous trading session at $81.2. The stock traded with the average Volume of 584.62 Million at the end of last session.
REGENXBIO Inc. (NASDAQ:RGNX) has the Market Capitalization of 2.57 Billion. The Stock has its 52-week High of $85.10 and 52-Week Low of $23.25 and it touched its 52-week high on 07/10/18 and 52-Week Low on 02/06/18
The company reported its last earnings Actual EPS of $0.3/share. While, the analyst predicted that the company could provide an EPS of $1.23/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.93/share which shows an Earnings Surprise of -75.6 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated REGENXBIO Inc. (NASDAQ:RGNX) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 15.93% where SMA50 and SMA200 are 13.33% and 75.36% respectively.
The company shows its Return on Assets (ROA) value of 29.5%. The Return on Equity (ROE) value stands at 31.4%. While it’s Return on Investment (ROI) value is -41.5%.
REGENXBIO Inc. (NASDAQ:RGNX) currently has a Weekly Volatility of 6.46% percent while its Monthly Volatility is at 5.32% percent. While talking about Performance of the Stock, REGENXBIO Inc. currently has a Weekly performance of 9.8%, monthly performance percentage is 24.44 percent, Quarterly performance is 42.46 percent, 6 months performance shows a percent value of 167.11% and Yearly Performance is 202.42 percent.
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.